## Answer
(model generated chain of thought explanation)

The key information provided in the question is that the drugs bind to a clustered group of proteins, which add a phosphate group to an aromatic amino acid sidechain.

1. **Phosphate group addition**: The fact that the drugs add a phosphate group to an aromatic amino acid sidechain suggests that this process is involved in a metabolic pathway or biochemical reaction. This is a critical clue because it points towards enzymes or metabolic pathways that involve phosphate groups.

2. **Clustered proteins**: The clustering of proteins implies that there might be a specific protein complex or interaction involved, which could be related to the function of the drug class.

3. **Aromatic amino acid sidechain modification**: The addition of a phosphate group to an aromatic amino acid is characteristic of certain metabolic pathways, such as the kynurenine pathway, where tryptophan is converted into 5-hydroxytryptophan through the action of indoleamine 2,3-dioxygenase (IDO).

4. **Kynurenine pathway disorders**: The kynurenine pathway is involved in the metabolism of tryptophan and other amino acids. Disorders related to this pathway include kynurenine aciduria, a condition characterized by elevated levels of kynurenine and its metabolites in the urine.

Considering these points, the most likely disorder treated by this drug class would be **kynurenine aciduria**, which is associated with defects in the kynurenine pathway. This pathway is crucial for tryptophan metabolism, and disorders affecting it can lead to elevated levels of certain amino acids and their metabolites.

The other options are less directly related to the described mechanism:
- A. Brain tumors: While some cancer drugs target brain tumors, there's no direct link between this drug class and these tumors.
- B. HER2 negative breast cancer: This is a type of breast cancer that does not have an overexpression of the HER2 protein. The drug class in question is not directly related to HER2 targeting.
- C. Chronic myeloid leukemia (CML): CML is a type of blood and bone marrow cancer, but it's not directly related to the described mechanism of action.

Therefore, based on the information provided, the most likely disorder treated by this drug class is kynurenine aciduria.